newsfilter
← Latest News
GlobeNewswire·

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more